Guggenheim 3rd Annual Healthcare Innovation Conference - SPRUCE BIOSCIENCES INC

Financial Performance:

• Specific revenue, earnings, cash flow, or debt figures were not disclosed; however, management highlighted the acquisition of the Priority Review Voucher (PRV) from the FDA.
• Revenue outlook relies on monetizing the PRV via sale to fund US commercialization.
• Future financial obligations include tiered global milestone payments and royalties to Biomarin, estimated at $20–$30 million annually for the first two years, with total global milestones capped around $130 million.
• The product utilizes a fixed-dose, weight-independent formulation, contrasting with weight-based competitors.

Guidance and Future Outlook:

• BLA (Biologics License Application) submission to the FDA is scheduled for December 2024.
• Anticipates BLA acceptance in February 2025, with potential approval in late August or early September 2025.
• A confirmatory registration trial is already underway at the time of BLA submission to satisfy regulatory requirements, eliminating the need for post-approval recruitment.
• European commercialization strategy is being revamped in Q4 2024 via local distributors, partner agreements, or name-patient programs.
• Management targets a broad pricing strategy commensurate with disease severity, potentially falling between $1 million (weight-based competitor baseline) and $4 million (gene therapy baseline), favoring a lower price point to ensure access.

Business Segments and Product Lines:

• Lead asset: Tralcinase alpha, an enzyme replacement therapy for MPS3B (Sanfilippo B syndrome) in pediatric neurology.
• Mechanism: Fission protein tagged with truncated IGF-2 enabling neuronal and lysosomal penetration; delivered via CSF port/reservoir weekly or every other week.
• Manufacturing: PPQ (Process Performance Qualification) for Drug Substance (DS) completed; Drug Product (DP) PPQ in progress due to site transfer from Germany to Samsung Biologics (South Korea), aiming for completion by year-end and inclusion in the BLA review.
• Pipeline expansion: Preparing data on additional biomarkers (NFL, GM2, GM3) for presentation at the World Meeting in February 2025.
• Expanded access program initiated to allow patient access prior to commercial launch.

Market and Competitive Landscape:

• Addressable patient pool estimated at approximately 450 diagnosed patients in the US (out of ~1,400 MPS3 patients) based on preliminary claims database analysis.
• Patients are concentrated in ~15 NORD-approved lysosomal storage disease centers of excellence.
• Competition: Direct competitor Fayuvi (gene therapy for MPS3A) priced near $4M; Denali's MPS2 therapy priced near $1M (weight-based).
• No other approved therapies exist for MPS3B; market demand is high for life-transforming treatments.

Risks and Challenges:

• Regulatory: FDA may debate functional measures (cognition) regarding baseline imbalances in heterogeneous patient populations, though propensity score matching and modeling are employed to address this.
• Market: Potential under-diagnosis in rare diseases and the lack of a specific ICD-10 code for MPS3B until therapy approval.
• Operational: Complexities in managing global commercialization, particularly in the challenging European market.
• Financial: Reliance on PRV monetization proceeds to fund commercial operations; execution of milestone payments to Biomarin.

Management Commentary and Tone:

• Tone is highly confident, describing the regulatory package as "tight," "compelling," and "super strong" with no comparable products on the market.
• Management expressed certainty regarding the FDA alignment on the confirmatory trial status and the likelihood of full approval without an advisory committee (ACOMD) review.
• Emphasized robust engagement with stakeholders, patient groups, and caregivers.

Analyst Questions and Answers:

• BLA Composition: Clarified that the first PPQ run is included in the BLA, while the second PPQ (post-manufacturing site transfer) will be submitted during the review cycle.
• Biomarker Precedent: Confirmed that heparan sulfate reduction is a "reasonably likely to predict clinical benefit" endpoint with a clear regulatory precedent (referencing Xerava and Fayuvi).
• Patient Identification: Discussed methodology for estimating the 450-patient US pool and the concentration of care at centers of excellence.
• Pricing Strategy: Addressed the tension between high rare disease pricing and patient access, proposing a fixed-dose strategy to avoid the extreme costs associated with weight-based gene therapies.
• PRV Ownership: Confirmed Spruce Biosciences retains the Priority Review Voucher and intends to monetize it immediately upon approval.

Other Key Points:

• The confirmatory trial design was successfully negotiated with the FDA to ensure feasibility at the time of submission, a significant strategic win.
• The company is conducting its own natural history study rather than relying on external control arms, ensuring data quality.
• The drug's mechanism allows for stabilization of cognitive and adaptive behavior, with potential benefit for older patients where disease progression can be halted.
• Regulatory pathway leverages the Rare Pediatric Disease designation for the PRV.